PTPN14 and blood and lymph vessel stability
Protein tyrosine phosphatase non-receptor 14 in vascular stability and remodeling
This project looks at how the PTPN14 gene controls blood and lymph vessel stability to help people with vascular problems such as hereditary hemorrhagic telangiectasia and acute lung injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11289446 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are connecting human genetic data from people with vascular disorders to experiments in cells and animal models to see how PTPN14 affects endothelial and lymphatic cells. They will probe how PTPN14 interacts with YAP signaling and other molecular pathways that control vessel remodeling and leakiness. The team will relate genetic variants linked to pulmonary arteriovenous malformations in HHT patients to vessel behavior in lab models. Ultimately the work aims to explain why some people are more prone to vascular malformations or worse recovery after lung injury or severe infections like COVID-19.
Who could benefit from this research
Good fit: People with hereditary hemorrhagic telangiectasia, pulmonary arteriovenous malformations, or a history of acute lung injury would be the most relevant candidates for related patient-facing studies or future trials.
Not a fit: People without vascular or lymphatic disorders or those seeking immediate clinical treatments may not see direct benefits because much of this work is preclinical and mechanistic.
Why it matters
Potential benefit: If successful, the work could reveal targets to prevent or repair blood vessel leaks and malformations, potentially improving treatments for HHT, pulmonary AVMs, and acute lung injury.
How similar studies have performed: Previous human genetics linked PTPN14 to pulmonary AVMs in HHT and experimental work implicates YAP pathway regulation, but translating these findings toward therapies remains early and exploratory.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Akhurst, Rosemary J — University of California, San Francisco
- Study coordinator: Akhurst, Rosemary J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.